Anbio Biotechnology (NNNN) Stock Analysis
Falling Knife setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $12.46 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Expensive valuation.
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry... Read more
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $12.46 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Expensive valuation. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Score 5.5/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $12.46 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Expensive valuation. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Prior stop was $11.81. Score 5.5/10, moderate confidence.
Take-profit target: $29.40 (+131.5% upside). Prior stop was $11.81. Stop-loss: $11.81.
Expensive valuation; Negative momentum; Below 200-MA, MA slope -12.5%/30d (confirmed downtrend).
Anbio Biotechnology trades at a P/E of 84.7 (forward N/A). TrendMatrix value score: 0.8/10. Verdict: Sell.
What does Anbio Biotechnology do?Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North...
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.